XML 60 R40.htm IDEA: XBRL DOCUMENT
v3.22.4

Acquisition of Ascyrus (Narrative) (Details) $ in Thousands |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Sep. 02, 2020 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2022 USD ($) item | Dec. 31, 2021 USD ($)
Business Acquisition [Line Items] |  |  |  |
Noncurrent portion of contingent consideration |  | $ 49,400 | $ 40,400 | $ 49,400
Ascyrus Medical LLC |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Equity ownership percent | 100.00% |  |  |
Contingent consideration, fair value adjustment |  |  | 9,000 | 9,500
Noncurrent portion of contingent consideration |  | 49,400 | $ 40,400 | $ 49,400
Ascyrus Medical LLC | Measurement Input, Discount Rate |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Contingent consideration, measurement input | item |  |  | 0.12 |
Ascyrus Medical LLC | FDA Approval IDE for AMDS |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | $ 60,000 | 10,000 |  |
Common stock value issued in business combination | 20,000 | $ 10,000 |  |
Ascyrus Medical LLC | FDA Approval IDE for AMDS | Maximum |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Aggregate amount of consideration transferred | 200,000 |  |  |
Ascyrus Medical LLC | FDA Approves Premarket Approval |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 10,000 |  |  |
Common stock value issued in business combination | 10,000 |  |  |
Ascyrus Medical LLC | AMDS Obtained In Japan |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 25,000 |  |  |
Ascyrus Medical LLC | AMDS Obtained In China |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 10,000 |  |  |
Ascyrus Medical LLC | If Japan Or China Obtains Approval |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 10,000 |  |  |
Ascyrus Medical LLC | Additional Potential Cash Payment If Japan Or China Obtains Approval |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 55,000 |  |  |
Ascyrus Medical LLC | Additional Potential Cash Payment If Japan Or China Obtains Approval | Maximum |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 75,000 |  |  |
Ascyrus Medical LLC | Additional Potential Cash Payment If Japan Or China Obtains Approval | Minimum |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | $ 65,000 |  |  |
Ascyrus Medical LLC | Following FDA Approval For AMDS |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Aggregate amount of consideration transferred |  |  | $ 120,000 |
Period of required contingent consideration | 3 years |  |  |

X
- Definition Business Combination, Contingent Consideration, Period + References No definition available. + Details
Name: | aort_BusinessCombinationContingentConsiderationPeriod
Namespace Prefix: | aort_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent Consideration, Fair Value Adjustment + References No definition available. + Details
Name: | aort_ContingentConsiderationFairValueAdjustment
Namespace Prefix: | aort_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of input used to measure contingent consideration liability from business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aort_AscyrusMedicalLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_FdaApprovalIdeForAmdsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_FdaApprovesPremarketApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_AmdsObtainedInJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_AmdsObtainedInChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_IfJapanOrChinaObtainsApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_AdditionalPotentialCashPaymentIfJapanOrChinaObtainsApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_FollowingFdaApprovalForAmdsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |